Clinical InvestigationCongestive Heart FailurePrognostic role of highly sensitive cardiac troponin I in patients with systolic heart failure
Section snippets
Patients
The subjects were 258 consecutive symptomatic CHF patients (left ventricular ejection fraction [LVEF] <45%) as previously reported.13, 14 Patients with recent (within 2 months) ischemic heart disease, those on dialysis therapy, and patients with high creatinine (≥2.5 mg/dL) were excluded. Informed consent was obtained from all patients before participation in the study, and the protocol was approved by the Human Investigations Committee of our institution. New York Heart Association (NYHA)
Patient characteristics
Table I summarizes patient characteristics according to survival. During a median follow-up of 2.6 years, 20 patients died of cardiac-related causes. Of 258 CHF patients, serum cTnT concentrations were elevated (≥0.03 ng/mL) in 32 patients (12%) and serum hs-cTnI concentrations were elevated (≥0.03 ng/mL) in 112 patients (43%). Kaplan-Meier curves for cardiac death by cTnT and hs-cTnI are shown in Figure 1. There was a significant correlation between log cTnT and log hs-cTnI in 32 patients in
Discussion
In this study, we demonstrated for the first time the prognostic value of hs-cTnI in patients with CHF. We measured serum concentrations of cTnT (fourth-generation Elecsys Troponin T immunoassay; Roche Diagnostics) and measured serum hs-cTnI (Siemens Healthcare Diagnostics) in the same 258 CHF patients with a low LVEF (<45%). In these patients, serum cTnT concentrations were elevated (≥0.03 ng/mL) in 32 patients (12%) and serum hs-cTnI concentrations were elevated (≥0.03 ng/mL) in 112 patients
Acknowledgements
We wish to thank Ms. Yohko Watanabe for excellent technical assistance. We also express thanks to Mr. Daniel Mrozek for assistance in preparing the manuscript.
References (24)
- et al.
High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure
J Am Coll Cardiol
(2000) - et al.
Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group
J Am Coll Cardiol
(2001) - et al.
Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure
Am J Cardiol
(2002) - et al.
Use of cytosolic and myofibril markers in the detection of ongoing myocardial damage in patients with chronic heart failure
Am J Med
(2002) - et al.
Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure
J Am Coll Cardiol
(2006) - et al.
Relationship between anemia, cardiac troponin I, and B-type natriuretic peptide levels and mortality in patients with advanced heart failure
Am Heart J
(2005) - et al.
Usefulness of B-type natriuretic peptide and cardiac troponin levels to predict in-hospital mortality from ADHERE
Am J Cardiol
(2008) - et al.
Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction
Circulation
(1997) - et al.
Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT)
Circulation
(2003) - et al.
Persistently increased serum concentrations of cardiac troponin t in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes
Circulation
(2001)
is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure
Circulation
Prognostic value of combination of cardiac troponin T and B-type natriuretic peptide after initiation of treatment in patients with chronic heart failure
Clin Chem
Cited by (96)
Biomarkers in Heart Failure: Clinical Insights
2021, Heart Failure ClinicsCitation Excerpt :Increased high-sensitivity cTn level was an independent risk factor for mortality and adverse outcome in patients with CHF in several studies. Troponin level increase may be useful in predicting mortality in patients with CHF and may have a complementary role to NP measurement in this context.66–68 In summary, cTn levels are associated with an increased risk of morbidity and mortality in both acute HF and CHF, providing incremental prognostic information.
Discovery of novel urea-diarylpyrazole hybrids as dual COX-2/sEH inhibitors with improved anti-inflammatory activity and highly reduced cardiovascular risks
2020, European Journal of Medicinal ChemistryCitation Excerpt :All the obtained results were shown in Table 4 and Fig. 4. The results revealed that celecoxib administration induced significant increase in the diagnostic biomarkers of myocardial damage [53–55] including Tn-I, LDH and CK-MB levels, as compared to normal control. Whereas, both 9b and 9c exhibited a significant lowering in these biochemical levels when compared to celecoxib treatment levels proofing their protective cardiovascular activity and much less risks.
High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure
2019, International Journal of Cardiology